| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 144 |
| 13 Nov 2026 |
Form 4: Anders Jack, Chief Financial Officer
Received 35,750 shares by exercise or conversion ($1.04M) · Sold 35,750 shares ($6.72M) |
| 13 Nov 2026 |
Form 4: Borisy Alexis, Director
Gave 10,625 shares as a gift |
| 12 Nov 2026 |
Form 4: Mancini Anthony, See Remarks
Received 811 shares by exercise or conversion ($27.3K) · Sold 811 shares ($162K) |
| 12 Nov 2026 | 144 |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy |
| 30 Oct 2026 | SCHEDULE 13G |
| 28 Oct 2026 |
Form 4: Mancini Anthony, See Remarks
Received 2,310 shares by exercise or conversion ($77.7K) · Sold 2,310 shares ($432K) |
| 13 Oct 2026 |
8-K: Creation of a Direct Financial Obligation; Other Events
The information set forth under Item 8.01 below under the heading “Royalty Pharma Tranche A Loan” is incorporated by reference into this Item 2.03. |
| 01 Oct 2026 |
Form 4: Sandler Alan B., Chief Development Officer
Received 6,000 shares by exercise or conversion ($353K) · Sold 6,309 shares ($1.28M) |
| 29 Sep 2026 |
Form 4: Cislini Jeff, SVP & General Counsel
Sold 765 shares ($159K) |
| 29 Sep 2026 | 144 |
| 28 Sep 2026 |
Form 4: Mancini Anthony, See Remarks
Sold 587 shares ($117K) · Received 3,121 shares by exercise or conversion ($105K) · Sold 3,121 shares ($626K) |
| 25 Sep 2026 | 144 |
| 24 Sep 2026 |
Form 4: Anderson Elizabeth M, Director
Received 5,070 shares by exercise or conversion ($5.68K) · Sold 10,143 shares ($1.96M) |
| 24 Sep 2026 | 144 |
| 22 Sep 2026 |
Form 4: Mancini Anthony, See Remarks
Sold 1,764 shares ($347K) |
| 22 Sep 2026 | 144 |
Loading...